PharmAla Biotech (CSE: MDMA) is pleased to announce that it has signed on to act as exclusive supplier of both GMP LaNeo™ MDMA and Engineering MDMA to InterVivo Solutions (Toronto), its client companies and Affiliates. InterVivo Solutions is a well-established pre-clinical contract research organization (CRO) with expertise in neuropsychiatric and neurological diseases. Together with Transpharmation, they form the largest boutique neuroscience-specialized in vivo CRO.

“We’re pleased to be able to offer our global client base a reliable and high-quality supply of reference MDMA through this exclusive supply agreement with PharmAla. Our hope is this will streamline and further propel our client’s research efforts to uncover and optimize the key properties of psychedelics and entactogenic medicines.”

Sal Lemus, Director of Sales and Marketing at InterVivo Solutions

Through this agreement, PharmAla will provide both its GMP, clinical-grade LaNeo™ MDMA to InterVivo and its client companies, as well as engineering MDMA for animal research. The agreement allows for simple access to MDMA for research purposes for all of InterVivo’s clients at reduced prices, and guarantees access to MDMA that can be taken all the way from pre-clinical to clinical, human research.

“As a current client of InterVivo, we have seen the excellence of their work first-hand. We’ve been impressed with both their scientific rigour, and the speed with which they have developed data sets to support our novel IP,” “I’m thrilled that we have been named the exclusive supplier of MDMA for both InterVivo and their research clients – and I’m sure that those clients will appreciate having a stable source of drug to support their efforts.”

 Nick Kadysh, PharmAla’s CEO

For more information, please visit www.PharmAla.ca, where you can sign up to receive regular new updates.

About PharmAla

PharmAla Biotech Holdings Inc. (CSE: MDMA) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials, and to develop novel drugs in the same class. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators. Our team of dedicated professionals includes regulatory experts, scientists, and biomanufacturing professionals. PharmAla has built what it believes to be North America’s first cGMP MDMA value chain, encompassing GMP manufacturing of Active Pharmaceutical Ingredient (API), and drug product formulation. PharmAla’s research and development unit has also begun preclinical research into two patented Novel Chemical Entities (NCEs) based on MDXX class molecules, with proof-of-concept research currently ongoing at the University of Arkansas School for Medical Sciences in the United States and at InterVivo Solutions in Canada. For more information, visit www.PharmAla.ca.

About InterVivo Solutions

InterVivo Solutions (IVS) is a preclinical in vivo CRO providing research services using translational animal models for efficacy, pharmacokinetics, safety and toxicology, including bioanalytical and imaging support. Together with its sister company, Transpharmation, IVS employs upwards of 120 qualified staff trained to support the scientific operations of the company across its’s locations in Canada, the UK, Ireland and Poland.
For more information, visit www.Intervivo.com and www.transpharmation.co.uk